Guideline says some early puberty cases may need less testing

The Endocrine Society is advising clinicians to tailor testing and treatment for children who enter puberty unusually early, saying some cases can be watched before doctors order more involved exams or prescribe medication. The guidance matters because central precocious puberty can affect adult height and may be linked to later physical and emotional health risks, according to the society.

The society released its clinical practice guideline on central precocious puberty on June 13. It was published online and is being presented at ENDO 2026, the society’s annual meeting, with publication planned in The Journal of Clinical Endocrinology & Metabolism.

Central precocious puberty occurs when the brain starts puberty-related hormone signals too soon, the guideline authors said. The society defines that timing as before age 8 in girls and before age 9 in boys.

Those signals can lead to breast development in girls, testicular enlargement in boys, faster growth and, in some cases, early menstruation, according to the Endocrine Society. The group said early puberty can affect final adult height and is associated with psychosocial stress, cardiovascular disease and some cancers later in life.

Observation may be enough in some cases

The guideline’s writing group chair, Ana Claudia Latronico of the University of São Paulo, said clinicians should assess children carefully so care is matched to the child’s condition while avoiding tests or treatments that are not needed. The society said the guideline is meant to help clinicians identify central precocious puberty, consider its causes and decide when treatment is appropriate.

Stephanie Roberts of Boston Children’s Hospital, co-chair of the writing group, said some children do not require the same level of evaluation or intervention as others. The society cited older girls whose puberty is progressing slowly as one group that often reaches normal adult height without treatment.

The Endocrine Society said puberty-pausing medicines can be effective for some children. The drugs temporarily suppress the brain signals that start puberty, and the guideline authors said treatment has the potential to improve adult height as well as psychosocial and long-term health outcomes in children with early puberty.

Key recommendations

The guideline offers several suggestions aimed at reducing unnecessary or invasive care while still identifying children whose puberty is advancing quickly, according to the Endocrine Society.

• For girls with early breast development, clinicians should consider physical exams every four to six months before starting diagnostic testing, the society said.
• For girls younger than 7, the guideline suggests four to six months of observation to help distinguish slow progression from rapid progression, because slow progression often ends with normal adult height without treatment.
• The society recommends a basal luteinizing hormone blood test as a simpler first-line test rather than GnRH agonist stimulation testing.
• The guideline advises against routine brain MRI in older children without neurological symptoms, defining that group as girls older than 6 and boys older than 7.
• The society says genetic testing should not be routine, especially when there is no family history of early puberty.
• When long-term therapy is expected, the guideline recommends starting with longer-acting puberty-delaying medications rather than shorter-acting options.
• The society advises against routine use of growth hormone therapy and against frequent lab monitoring during treatment unless clinicians suspect treatment failure.
• The guideline says therapy should be stopped by early adolescence, around ages 10 to 11 in girls and 11 to 12 in boys.

The Endocrine Society said the recommendations are designed to help doctors individualize care, including using observation, simpler tests and medication when the child’s clinical course supports treatment.

This story draws on original reporting from Medical Xpress.